NCT01093677View on ClinicalTrials.gov

Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance

PHASE1WithdrawnINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions

Impaired Glucose Tolerance

Interventions

DRUG

LIM-0705

Oral solution 750 mg LIM 0705 BID for 14 days.

DRUG

Placebo

Oral solution placebo BID for 14 days.

Sponsors

Lead Sponsor

Limerick BioPharma

All Listed Sponsors

lead

Limerick BioPharma

INDUSTRY